Johnson & Johnson - Asset Resilience Ratio
Johnson & Johnson (JNJ) has an Asset Resilience Ratio of 2.92% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Johnson & Johnson debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1994–2024)
This chart shows how Johnson & Johnson's Asset Resilience Ratio has changed over time. See shareholders equity of Johnson & Johnson for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Johnson & Johnson's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Johnson & Johnson (JNJ) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $5.30 Billion | 2.75% |
| Short-term Investments | $331.00 Million | 0.17% |
| Total Liquid Assets | $5.63 Billion | 2.92% |
Asset Resilience Insights
- Limited Liquidity: Johnson & Johnson maintains only 2.92% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Johnson & Johnson Industry Peers by Asset Resilience Ratio
Compare Johnson & Johnson's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
AstraZeneca PLC
NASDAQ:AZN |
Drug Manufacturers - General | 5.03% |
|
Novartis AG
MX:NVSN |
Drug Manufacturers - General | 0.09% |
|
Novartis AG ADR
NYSE:NVS |
Drug Manufacturers - General | 10.03% |
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 7.18% |
|
Virbac SA
PA:VIRP |
Drug Manufacturers - General | 0.23% |
|
Yifan Xinfu Pharmaceutical Co Ltd
SHE:002019 |
Drug Manufacturers - General | 0.53% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 8.63% |
Annual Asset Resilience Ratio for Johnson & Johnson (1994–2024)
The table below shows the annual Asset Resilience Ratio data for Johnson & Johnson.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 3.63% | $6.54 Billion | $180.10 Billion | +0.12pp |
| 2023-12-31 | 3.51% | $5.88 Billion | $167.56 Billion | -4.37pp |
| 2022-12-31 | 7.88% | $14.76 Billion | $187.38 Billion | -2.57pp |
| 2021-12-31 | 10.45% | $19.02 Billion | $182.02 Billion | +2.84pp |
| 2020-12-31 | 7.61% | $13.30 Billion | $174.89 Billion | +4.53pp |
| 2019-12-31 | 3.07% | $4.85 Billion | $157.73 Billion | -0.18pp |
| 2018-12-31 | 3.25% | $4.98 Billion | $152.95 Billion | +0.23pp |
| 2017-12-31 | 3.03% | $4.76 Billion | $157.30 Billion | -18.31pp |
| 2016-12-31 | 21.33% | $30.12 Billion | $141.21 Billion | +2.86pp |
| 2015-12-31 | 18.47% | $24.64 Billion | $133.41 Billion | +4.23pp |
| 2014-12-31 | 14.24% | $18.57 Billion | $130.36 Billion | +8.00pp |
| 2013-12-31 | 6.24% | $8.28 Billion | $132.68 Billion | +1.15pp |
| 2012-12-31 | 5.09% | $6.18 Billion | $121.35 Billion | -1.70pp |
| 2011-12-31 | 6.79% | $7.72 Billion | $113.64 Billion | -1.28pp |
| 2010-12-31 | 8.07% | $8.30 Billion | $102.91 Billion | +4.25pp |
| 2009-12-31 | 3.82% | $3.62 Billion | $94.68 Billion | +1.41pp |
| 2008-12-31 | 2.40% | $2.04 Billion | $84.91 Billion | +0.50pp |
| 2007-12-31 | 1.91% | $1.54 Billion | $80.95 Billion | +1.91pp |
| 2006-12-31 | 0.00% | $1.00 Million | $70.56 Billion | -0.14pp |
| 2005-12-31 | 0.14% | $83.00 Million | $58.86 Billion | -6.76pp |
| 2004-12-31 | 6.90% | $3.68 Billion | $53.32 Billion | -1.69pp |
| 2003-12-31 | 8.59% | $4.15 Billion | $48.26 Billion | -2.71pp |
| 2002-12-31 | 11.30% | $4.58 Billion | $40.56 Billion | +0.35pp |
| 2001-12-31 | 10.95% | $4.21 Billion | $38.49 Billion | +3.71pp |
| 2000-12-31 | 7.24% | $2.48 Billion | $34.24 Billion | +2.04pp |
| 1999-12-31 | 5.20% | $1.52 Billion | $29.16 Billion | +2.31pp |
| 1998-12-31 | 2.89% | $789.00 Million | $27.29 Billion | +2.21pp |
| 1997-12-31 | 0.68% | $146.00 Million | $21.45 Billion | +0.06pp |
| 1996-12-31 | 0.62% | $125.00 Million | $20.01 Billion | +0.19pp |
| 1994-12-31 | 0.43% | $68.00 Million | $15.67 Billion | -- |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bow… Read more